再生医学与基因治疗进展

The World Governments Summit is a global platform dedicated toshaping the future of governments worldwide. Each year, the Summitsets the agenda for the next generation of governments with a focuson how they can harness innovation and technology to solve universalchallenges facing humanity.The World Governments Summit is a knowledge exchange center atthe intersection of government, futurism, technology, and innovation.It functions as a thought leadership platform and networking hub forpolicymakers, experts and pioneers in human development.The Summit is a gateway to the future as it functions as the stage foranalysis of future trends, concerns, and opportunities facing humanity.It is also an arena to showcase innovations, best practice, and smartsolutions to inspire creativity to tackle these future challenges.To Inspireand EnableThe Next Generationof Governments01World Governments Summit 02 Table of ContentsExecutive SummaryThe Rise Of RM And Gene Therapy In ADeepening Global Healthcare CrisisHow Regenerative Medicine And Gene TherapyCan Ease The World’s Health BurdenConclusion: Collaboration AndCo-Operation: The Keys To Realizing TheFull Potential Of RM And Gene TherapyRegulators Need To Be RM And Gene TherapyEnablers As Well As Rule-MakersTopicsRM And Gene Therapy Cost-Benefit Analysis – HarderThan Conventional Healthcare Budget PlanningArtificial Intelligence (AI) And NewDigital Medical TechnologiesCase Study 2: UAE. Leveraging Digital TransformationTo Build A Significant RM And Gene Therapy HubChildren, RM, And Gene Therapy: A Moral ImperativeAddressing Affordability: Governments,Industry, Healthcare Providers, And RegulatorsMust Work Together To Deliver Cost-EffectiveRM And Gene Therapy HealthcareCase Study 3: Australia. Targeted GovernmentInvestment In Specific RM And Gene Therapy SectorsInnovationIncreasing Life ExpectancyThe Cost Of Healthcare Is SpiralingCase Study 1: Japan. How A Faster RegulatoryPathway For RM And Gene Therapy CouldImprove Healthcare For Older PeopleNoncommunicable Diseases (NCDs)Rare DiseasesRM And Gene Therapy: Essential Tools ForAddressing The Global Health Burden 050915272317181920212122111012131314 In December 1967, when Dr Christiaan Barnard and a team of surgeonsperformed the first human heart-to-heart transplant, the medical landmarkmade front-page news around the world. Today, advances in regenerativemedicine (RM) and gene therapy (see box 1) are so routine that they aretypically only covered by specialist scientific and industry journals.However, governments, healthcare providers (HCPs), and medicalprofessionals cannot afford to ignore the latest developments in RMand gene therapy because they are one of the most promising pathwaysto ensuring better lifelong health and quality of life for all citizens.Treatments for genetic disorders, tissue regeneration techniques, andorgan replacements are just some of the areas where RM and genetherapy are already helping to shift healthcare in developed countriesfrom symptomatic to curative treatments that are less costly in the longterm. Prevention is the ultimate objective, aiming to minimize healthcarecosts, and precision medicine – especially with RM and gene therapyplaying an increasingly important role – can be leveraged in combatingrare diseases and non-communicable diseases (NCDs) such as cancers.Two accelerating trends mean that governments must act now to maximizethe potential benefits of RM and gene therapy before it is too late. First,healthcare budgets worldwide are spiraling out of control in both developedand developing countries. The reasons are complex and interconnected.They include increased life expectancy, the rise of non-communicableand rare diseases as a global health burden, and the impact of COVID-19.RM and gene therapy are relevant to all these challenges, providing anincreasing number of treatments that are more cost-effective and deliverbetter long-term outcomes for patients than conventional medicine.Second, the remarkable advances in RM and gene therapy are connected to theemergence of digital scientific and medical technologies and processes such asgene editing and AI-enabled surgical devices. These technologies are evolvingat such speed that governments cannot afford to sit on the sidelines while othercountries secure a head start in investing in RM and gene therapy, from thelaboratory to the hospital bedside. The policy-making and budgetary dilemma,which we examine in this report, is how to balance the high initial R&D costsof RM and gene therapy against the considerable long-term cost benefits.Executive Summary World Government Summit We make the following key recommendations forgovernments, drawing on academic and clinical RMand gene therapy policy research and examples ofbest practice from around the world:Ensure healthcare providers havesufficient digital technology andexpertise to deliver RM and genetherapy.Recruit clinical and PLS industryspecialists to advise and informhealth ministries